Redvax Overview

  • Status
  • Acquired/​Merged
  • Latest Deal Type
  • M&A

Redvax General Information

Description

Operator of a biopharmaceutical company in Sweden. The company develops multi-component virus-like particles (VLPs) and other protein assemblies for vaccine development in the field of Cytomegalovirus (CMV).

Contact Information

Ownership Status
Acquired/Merged
Financing Status
Formerly VC-backed
Primary Industry
Drug Discovery
Other Industries
Biotechnology
Pharmaceuticals
Acquirer
Pfizer
Primary Office
  • Wagistrasse 23
  • Schlieren
  • 8952 Zurich
  • Switzerland
Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Redvax Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Merger/Acquisition 05-Jan-2015 Completed Pre-Clinical Trials
1. Early Stage VC Completed Startup
To view Redvax’s complete valuation and funding history, request access »

Redvax Executive Team (1)

Name Title Board Seat Contact Info
Christian Schaub Managing Director
To view Redvax’s complete executive team members history, request access »

Redvax Former Investors (1)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Redalpine Venture Partners Venture Capital Minority 000 0000 000000 0
To view Redvax’s complete investors history, request access »

Ready to get started?

Request a free trial